

Umeå, Sweden, 16 May 2011

## **Life Science company from Umeå makes a touchdown on the global arena**

**Having received CE marked, Umeå based Life Science company BioResonator has sold around fifty devices for measuring intraocular pressure – the Tonometer ART<sup>®</sup> – since the beginning of 2011.**

BioResonator intraocular pressure (IOP) device, ART<sup>®</sup>, will simplify glaucoma follow-up and advance the diagnostics. ART<sup>®</sup> is based on a patented resonance technology and is considerably more flexible to use, compared with the in many ways outdated technology that eye clinics are reduced to using today. Another advantage of the BioResonator IOP device is that it works on laser operated corneas. The product enables a simple and very effective way of measuring intraocular pressure. The ART<sup>®</sup> provides exact IOP measurements and is easy to use regardless of who performs the reading. No training is needed. The ART<sup>®</sup> method is also less dependent on cornea thickness and biomechanical characteristics, and requires no fluorescein – the yellow dye that is administered to the eye in the current standard method.

The ART<sup>®</sup> tonometer has been delivered to 16 European countries and has also been exported for clinical studies outside the EU.

"Orders are coming in in larger volumes and key opinion leaders in several parts of the world are demanding the product," says Mikael Lindblad, CEO of BioResonator, recently returned from a North American business trip during which BioResonator participated at a U.S. eye conference and visited distributors in Canada and the U.S.

### **ART<sup>®</sup> products**

The ART<sup>®</sup> products consist of tonometer devices used to measure intraocular pressure (IOP). An increased IOP measure may be a sign of the disease glaucoma which damages the optical nerve and can lead to blindness if left untreated. In the Western world appr. 6 percent of the population above 70 suffer from glaucoma<sup>1</sup> and eye pressure measurement is a routine examination at eye specialist clinics, health care centers, private clinics and optician's. Many carry the disease unknowingly and don't seek care until they are symptomatic. The number of undiscovered cases may be as large as 50 percent<sup>2</sup>. A glaucoma patient needs lifelong treatment and regular eye pressure exams. The products introduced to the market is the base model ART<sup>®</sup> Manual and ART<sup>®</sup> Servo that is fully automated for even easier use.

**For more information, please contact:**

**Mikael Lindblad, CEO, +46 730-584620**

Email: [mikael.lindblad@bioresonator.com](mailto:mikael.lindblad@bioresonator.com)

### **About BioResonator**

BioResonator's business concept is to develop and market diagnostic systems based on sensor technology for the health and medical care. BioResonator is owned by LinkMed, Karolinska Development and private entities. Read more about BioResonator at [www.bioresonator.com](http://www.bioresonator.com)

---

<sup>1</sup> Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian metaanalysis. Invest Ophthalmol Vis Sci 2006;47:4254-61.

<sup>2</sup> Ekstrom C. Prevalence of open-angle glaucoma in central Sweden. The Tierp Glaucoma Survey. Acta Ophthalmol Scand 1996;74:107-12.